ION337
Sponsors
Ionis Pharmaceuticals Inc., Ionis Pharmaceuticals, Inc.
Conditions
Dravet Syndrome
Phase 1
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
RecruitingNCT07531745
Start: 2026-05-21End: 2030-12-01Target: 32Updated: 2026-09-03
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome
Not yet recruitingCTIS2025-523835-20-00
Target: 5Updated: 2026-07-01